ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 394
- Registration Number
- NCT05274100
- Locations
- 🇺🇸
PPD Clinical Research Unit - Austin /ID# 222361, Austin, Texas, United States
🇺🇸Altasciences Clinical Los Angeles, Inc /ID# 222238, Cypress, California, United States
🇺🇸Anaheim Clinical Trials LLC /ID# 222821, Anaheim, California, United States
A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China
- First Posted Date
- 2022-03-07
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 30
- Registration Number
- NCT05268068
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital /ID# 212830, Shanghai, Shanghai, China
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 263
- Registration Number
- NCT05264129
- Locations
- 🇺🇸
Advanced Research Institute - Ridgeline /ID# 242662, Ogden, Utah, United States
🇺🇸Clinvest Research LLC /ID# 242597, Springfield, Missouri, United States
🇺🇸Aventiv Research Columbus /ID# 242462, Columbus, Ohio, United States
A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 986
- Registration Number
- NCT05248893
- Locations
- 🇺🇸
Perelman Center for Advanced Medicine - /ID# 243966, Philadelphia, Pennsylvania, United States
🇺🇸Northwest Dermatology Institute /ID# 233498, Portland, Oregon, United States
🇺🇸Swinyer-Woseth Dermatology /ID# 241250, Salt Lake City, Utah, United States
A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 638
- Registration Number
- NCT05248867
- Locations
- 🇺🇸
Clinical Testing of Beverly Hills /ID# 233195, Encino, California, United States
🇺🇸Westside Aesthetics /ID# 232443, Los Angeles, California, United States
🇺🇸Steven Fagien MD Aesthetic Eyelid Plastic Surgery /ID# 232439, Boca Raton, Florida, United States
A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
- Conditions
- Schizophrenia
- Interventions
- Drug: CVL-231 10 mgDrug: Required CVL-231 30 mgDrug: Placebo
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 385
- Registration Number
- NCT05227690
- Locations
- 🇺🇸
Oakland Park, Florida, Oakland Park, Florida, United States
🇺🇸DeSoto, Texas, DeSoto, Texas, United States
🇺🇸Richardson, Texas, Richardson, Texas, United States
A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
- Conditions
- Schizophrenia
- Interventions
- Drug: Required CVL-231 30 mgDrug: CVL-231 15 mgDrug: Placebo
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 391
- Registration Number
- NCT05227703
- Locations
- 🇭🇺
Kalocsa, Bács-Kiskun, Kalocsa, Bács-Kiskun, Hungary
🇺🇸Miami, Florida, Miami, Florida, United States
🇺🇸Bellflower, California, Bellflower, California, United States
An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) in Adult Participants With Moderately to Severely Active Primary Sjogren's Syndrome (pSS)
- Conditions
- Sjogren's Syndrome (SS)
- Interventions
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- AbbVie
- Registration Number
- NCT05217472
- Locations
- 🇳🇱
Universitair Medisch Centrum Utrecht /ID# 214029, Utrecht, Netherlands
Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor
- Conditions
- Upper Limb Essential Tremor (UL ET)
- Interventions
- Drug: Placebo for BOTOX
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 174
- Registration Number
- NCT05216250
- Locations
- 🇺🇸
Accel Research Sites - Neurology and Neurodiagnostics of Alabama, LLC /ID# 240472, Hoover, Alabama, United States
🇺🇸Barrow Neurological Institute - Dignity Health St. Joseph's Hosp and Medical Ctr /ID# 231731, Phoenix, Arizona, United States
🇺🇸University of Arizona /ID# 239781, Tucson, Arizona, United States
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax Tablets
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 125
- Registration Number
- NCT05215639
- Locations
- 🇦🇹
Klinikum Klagenfurt am Wörthersee /ID# 247304, Klagenfurt am Wörthersee, Kaernten, Austria
🇨🇭Duplicate_Universitätsspital Basel /ID# 256509, Basel, Basel-Stadt, Switzerland
🇨🇭Inselspital, Universitaetsspital Bern /ID# 239241, Bern, Switzerland